Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2001

View Archived Issues

INOmax approved in Europe for treating critically ill newborns

Neuroprotective activity of estrogens and SERMs examined at congress

Enrollment begins in new clinical trials of 7-day combination contraceptive patch

Bristol-Myers Squibb selects potential drug targets from Lexicon's LexVision database

Periostat tablets for periodontitis granted dental practitioners formulary status in the UK

Enrollment completed in novel trial for prevention of hypertension

Clinical program for Vitrix living dermal replacement begins

Product R enhances production and secretion of proinflammatory chemokines in human monocytes

Rituximab tested as a treatment for chronic ITP

Pfizer describes erythromycin A derivatives with antibacterial and antiprotozoal activity

New benzamidine derivatives with anticoagulant activity designed by Ajinomoto

Ajinomoto patents new series of factor VII inhibitors

New class of antibacterials reported by Ortho-McNeil

Venlafaxine ER shows good long-term results in GAD patients

First clinical trial of rhuCD40L in cancer patients completed

Approval of Remodulin recommended by the FDA for pulmonary arterial hypertension

FDA approves Natrecor for treatment of congestive heart failure

Zeltia and Ortho Biotech announce licensing agreement for ET-743

New antiarrhythmic agents identified at BMS

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...